Bone turnover markers (BTMs) are used widely, in both research and clinical practice. In the
last 20 years, much experience has been gained in measurement and interpretation of these …

THE ABNORMALITIES of the skeleton in chronic kidney disease (CKD), collectively known
as renal osteodystrophy, are an important cause of morbidity and decreased quality of life. In …

Abstract The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative
(KDOQI) has provided evidence-based guidelines for nutrition in kidney diseases since …

The National Kidney Foundation/Kidney-Dialysis Outcome Quality Initiative guidelines
recommend to maintain the serum intact parathyroid hormone (PTH) concentration between …

Background. Sclerostin is a soluble inhibitor of osteoblast function. Sclerostin is
downregulated by the parathyroid hormone (PTH). Here, it was investigated whether …

Hypophosphatemia is a common complication of kidney transplantation. Tertiary
hyperparathyroidism has long been thought to be the etiology, but hypophosphatemia can …

The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend that serum
parathyroid hormone (PTH) concentration of patients with chronic kidney disease (CKD) …

Uremic secondary hyperparathyroidism is a multifactorial and complex disease often
present in advanced stages of chronic kidney disease. The accumulation of phosphate, the …

Adynamic bone in patients with chronic kidney disease (CKD) is a clinical concern because
of its potential increased risk for fracture and cardiovascular disease (CVD). Prevalence …

Context: Fibroblast growth factor (FGF)-23 is produced in bone, and circulating levels are
markedly elevated in patients with end-stage kidney disease, but the relationship between …